Forest Laboratories, Gruenenthal deal

Gruenenthal granted Forest exclusive rights in the U.S. and Canada to co-develop and commercialize two candidates for pain. GRT 6005 and follow-on compound GRT 6006 are agonists of opioid receptor ...